Platelet transfusions are widely used. Prophylactic transfusions are employed in severely thrombocytopenic patients without evidence of bleeding, but no randomized trial data prove the safety or efficacy of this approach. Randomized trials have demonstrated the equivalence of transfusion triggers of
Platelet transfusion therapy
β Scribed by Lawrence Tim Goodnough
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 110 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0733-2459
- DOI
- 10.1002/jca.1011
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The relative merits of apheresis platelets and platelet concentrates are undergoing debate due to evolving issues of safety, inventory, and cost. The application of photochemical inactivation technology may eliminate any rationale for the use of apheresis platelets rather than pooled platelet concentrates, so that the relative merits of these two alternatives will be debated over costs and inventory. Doses of apheresis platelets are determined by donor platelet count and by platelet yield. The generation of a platelet apheresis inventory has been accompanied by a decline in whole blood inventory; research into the impact of these distinct donor pools on national blood policy is needed. J. Clin. Apheresis. 16:43β48, 2001. Β© 2001 WileyβLiss, Inc.
π SIMILAR VOLUMES
A kinetics model is proposed for platelet disposition after transfusion of platelets. In this model, transfusion of platelets and production of endogenous platelets contribute to an increase in the number of platelets in patients, and the life span and age of each platelet contribute to a decrease.
Platelet transfusions are an important supportive measure during treatment for acute nonlymphocytic leukemia (ANLL). The presence of splenomegaly may produce decreased posttransfusion platelet increments leading some to recommend an increased dose of platelets per transfusion in this situation. Fort